301 related articles for article (PubMed ID: 20382161)
1. Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion.
Johnson S; Burke S; Huang L; Gorlatov S; Li H; Wang W; Zhang W; Tuaillon N; Rainey J; Barat B; Yang Y; Jin L; Ciccarone V; Moore PA; Koenig S; Bonvini E
J Mol Biol; 2010 Jun; 399(3):436-49. PubMed ID: 20382161
[TBL] [Abstract][Full Text] [Related]
2. Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16).
Bruenke J; Barbin K; Kunert S; Lang P; Pfeiffer M; Stieglmaier K; Niethammer D; Stockmeyer B; Peipp M; Repp R; Valerius T; Fey GH
Br J Haematol; 2005 Jul; 130(2):218-28. PubMed ID: 16029450
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic control of B cell activation via recruitment of Fcgamma receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold.
Veri MC; Burke S; Huang L; Li H; Gorlatov S; Tuaillon N; Rainey GJ; Ciccarone V; Zhang T; Shah K; Jin L; Ning L; Minor T; Moore PA; Koenig S; Johnson S; Bonvini E
Arthritis Rheum; 2010 Jul; 62(7):1933-43. PubMed ID: 20506263
[TBL] [Abstract][Full Text] [Related]
4. Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells.
Würflein D; Dechant M; Stockmeyer B; Tutt AL; Hu P; Repp R; Kalden JR; van de Winkel JG; Epstein AL; Valerius T; Glennie M; Gramatzki M
Cancer Res; 1998 Jul; 58(14):3051-8. PubMed ID: 9679970
[TBL] [Abstract][Full Text] [Related]
5. Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation.
Cochlovius B; Kipriyanov SM; Stassar MJ; Schuhmacher J; Benner A; Moldenhauer G; Little M
Cancer Res; 2000 Aug; 60(16):4336-41. PubMed ID: 10969772
[TBL] [Abstract][Full Text] [Related]
6. A recombinant bispecific single-chain Fv antibody against HLA class II and FcgammaRIII (CD16) triggers effective lysis of lymphoma cells.
Bruenke J; Fischer B; Barbin K; Schreiter K; Wachter Y; Mahr K; Titgemeyer F; Niederweis M; Peipp M; Zunino SJ; Repp R; Valerius T; Fey GH
Br J Haematol; 2004 Apr; 125(2):167-79. PubMed ID: 15059139
[TBL] [Abstract][Full Text] [Related]
7. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics.
Kipriyanov SM; Moldenhauer G; Schuhmacher J; Cochlovius B; Von der Lieth CW; Matys ER; Little M
J Mol Biol; 1999 Oct; 293(1):41-56. PubMed ID: 10512714
[TBL] [Abstract][Full Text] [Related]
8. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
[TBL] [Abstract][Full Text] [Related]
9. In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti-CD3 x anti-idiotype) induces long-term survival in the murine BCL1 lymphoma model.
De Jonge J; Heirman C; de Veerman M; Van Meirvenne S; Moser M; Leo O; Thielemans K
J Immunol; 1998 Aug; 161(3):1454-61. PubMed ID: 9686611
[TBL] [Abstract][Full Text] [Related]
10. A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells.
Kellner C; Bruenke J; Stieglmaier J; Schwemmlein M; Schwenkert M; Singer H; Mentz K; Peipp M; Lang P; Oduncu F; Stockmeyer B; Fey GH
J Immunother; 2008; 31(9):871-84. PubMed ID: 18833000
[TBL] [Abstract][Full Text] [Related]
11. A recombinant bispecific single-chain fragment variable specific for HLA class II and Fc alpha RI (CD89) recruits polymorphonuclear neutrophils for efficient lysis of malignant B lymphoid cells.
Guettinger Y; Barbin K; Peipp M; Bruenke J; Dechant M; Horner H; Thierschmidt D; Valerius T; Repp R; Fey GH; Stockmeyer B
J Immunol; 2010 Feb; 184(3):1210-7. PubMed ID: 20042573
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy with bispecific antibodies.
Thielemans KM
Verh K Acad Geneeskd Belg; 1995; 57(3):229-47; discussion 247-8. PubMed ID: 7483816
[TBL] [Abstract][Full Text] [Related]
13. The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells.
Glorius P; Baerenwaldt A; Kellner C; Staudinger M; Dechant M; Stauch M; Beurskens FJ; Parren PW; Winkel JG; Valerius T; Humpe A; Repp R; Gramatzki M; Nimmerjahn F; Peipp M
Leukemia; 2013 Jan; 27(1):190-201. PubMed ID: 22660187
[TBL] [Abstract][Full Text] [Related]
14. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
Nielsen UB; Adams GP; Weiner LM; Marks JD
Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effects of a bispecific antibody targeting CA19-9 antigen and CD16.
Garcia de Palazzo I; Holmes M; Gercel-Taylor C; Weiner LM
Cancer Res; 1992 Oct; 52(20):5713-9. PubMed ID: 1394194
[TBL] [Abstract][Full Text] [Related]
16. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
Scheffold C; Kornacker M; Scheffold YC; Contag CH; Negrin RS
Cancer Res; 2002 Oct; 62(20):5785-91. PubMed ID: 12384539
[TBL] [Abstract][Full Text] [Related]
17. Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16.
Singer H; Kellner C; Lanig H; Aigner M; Stockmeyer B; Oduncu F; Schwemmlein M; Stein C; Mentz K; Mackensen A; Fey GH
J Immunother; 2010; 33(6):599-608. PubMed ID: 20551837
[TBL] [Abstract][Full Text] [Related]
18. CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis.
Mølhøj M; Crommer S; Brischwein K; Rau D; Sriskandarajah M; Hoffmann P; Kufer P; Hofmeister R; Baeuerle PA
Mol Immunol; 2007 Mar; 44(8):1935-43. PubMed ID: 17083975
[TBL] [Abstract][Full Text] [Related]
19. In vitro cytotoxic targeting by human mononuclear cells and bispecific antibody 2B1, recognizing c-erbB-2 protooncogene product and Fc gamma receptor III.
Hsieh-Ma ST; Eaton AM; Shi T; Ring DB
Cancer Res; 1992 Dec; 52(24):6832-9. PubMed ID: 1360872
[TBL] [Abstract][Full Text] [Related]
20. Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts.
Buchsbaum DJ; Wahl RL; Normolle DP; Kaminski MS
Cancer Res; 1992 Dec; 52(23):6476-81. PubMed ID: 1423295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
